HOME >> BIOLOGY >> NEWS
Dipstick test for meningitis culprits

Over a million people each year, most of them in the "meningitis belt" in Africa, contract bacterial meningitis, a potentially deadly infection of tissues that line the brain and spinal cord. The disease can be caused by several kinds of bacteria, and identifying the culprit early during an outbreak is critical to its containment. Suzanne Chanteau and colleagues in Niger have now developed a new series of simple and accurate tests that can determine the cause of an outbreak locally. As they describe in a research article in the international open-access medical journal PLoS Medicine, their "dipstick" tests require no fancy laboratory equipment, and not even refrigeration.

The tests, done on the patient's spinal fluid (which is obtained as a part of the routine evaluation of someone suspected of having meningitis) can determine whether the disease is caused by one of the four most common groups of meningococcus circulating in Africa. Two paper strips, the "dipsticks", are placed in two separate tubes of the patient's spinal fluid. After several minutes, the appearance of red lines on the dipsticks shows whether one of the four groups of meningococcus is present, and if so, which one.

The new dipstick test for meningococcal meningitis represents a major advance for health-care workers in remote locations affected by meningitis epidemics. This test can be stored without refrigeration and used at bedside in the hot temperatures typical of the African savannah during the meningitis season. The dipsticks are easier to use than currently available test kits, give more rapid results, and are more accurate. They promise to be an important tool for guiding individual treatment decisions as well as public health actions, including vaccine selection, against the perennial threat of epidemic meningitis.


'"/>

Contact: Andrew Hyde
ahyde@plos.org
Public Library of Science
4-Sep-2006


Page: 1

Related biology news :

1. Dipstick test could reduce risk of food poisoning by rapidly detecting spoilage
2. Hot on the TRAIL of controlling inflammation in bacterial meningitis
3. Scientists identify specific enzymes that make meningitis hard to fight
4. New bacterial gene provides meningitis mechanism
5. VaxGen and EndoBiologics form collaboration to pursue early stage research for meningitis B vaccine
6. Pollution trackers hit the road to pinpoint airborne culprits
7. Forsyth scientists find blue light fights gum disease culprits
8. Sniffing out the culprits of dust allergies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dipstick test for meningitis culprits

(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: